Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia

This study aimed to explore the influence of two genetic polymorphisms of the 5-hydroxytryptamine 1A receptor (5-HT1A) and solute carrier family 6, member 4 (SLC6A4) genes on the clinical symptoms and treatment resistance in Slovenian patients with schizophrenia. A total of 138 patients with schizop...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychiatric disease and treatment 2015-01, Vol.11 (default), p.453-459
Main Authors: Terzić, Tea, Kastelic, Matej, Dolžan, Vita, Plesničar, Blanka Kores
Format: Article
Language:English
Subjects:
Antipsychotics
Blood & organ donations
Cognition & reasoning
Dopamine
Equilibrium
Genes
genetic polymorphisms
Mental disorders
Neurosciences
Original Research
Patients
Polymorphism
Psychiatry
Psychotropic drugs
Schizophrenia
serotonergic receptor
serotonergic system
Serotonin
SLC6A4
Studies
Suicides & suicide attempts
Treatment resistance
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c476t-61c3449d2695e8ef0d2640dcdcfa7f598d2edbb5fdef38ebdbb519f6516e1593
cites
container_end_page 459
container_issue default
container_start_page 453
container_title Neuropsychiatric disease and treatment
container_volume 11
creator Terzić, Tea
Kastelic, Matej
Dolžan, Vita
Plesničar, Blanka Kores
description This study aimed to explore the influence of two genetic polymorphisms of the 5-hydroxytryptamine 1A receptor (5-HT1A) and solute carrier family 6, member 4 (SLC6A4) genes on the clinical symptoms and treatment resistance in Slovenian patients with schizophrenia. A total of 138 patients with schizophrenia were evaluated using the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Clinical Global Impression, and Global Assessment of Functioning. Based on the selected criteria, 94 patients were included in the treatment-responsive and 44 in the treatment-resistant group. All subjects and 94 controls were genotyped for the 5-HT1A rs6295 and 5-HTTLPR polymorphisms. There were no statistically significant differences in the frequencies of these polymorphisms between the patients with schizophrenia and the control group and between the treatment-resistant and treatment-responsive group of schizophrenia patients. Polymorphisms rs6295 and 5-HTTLPR had an influence on the Global Assessment of Functioning scale score, while 5-HTTLPR also had an influence on the total score of the negative subscale within the Positive and Negative Syndrome Scale. Although we found no effect on progression toward the treatment-resistant schizophrenia, our data suggest that the rs6295 and 5-HTTLPR polymorphisms can influence some clinical symptoms in schizophrenia.
doi_str_mv 10.2147/NDT.S76494
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_70fd0025097841998758d325bcf54f75</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_70fd0025097841998758d325bcf54f75</doaj_id><sourcerecordid>1668245177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-61c3449d2695e8ef0d2640dcdcfa7f598d2edbb5fdef38ebdbb519f6516e1593</originalsourceid><addsrcrecordid>eNqNUstuEzEUHSEQLYUNH4BGYlMhTfH7sUGqyqORIkCQveV4rpOJZsaDPROpbPlxnKSpSFesfHR97vG516coXmN0RTCT779-XFz9lIJp9qQ4x1iqiiCCn-6xqAQl6qx4kdIGISq1Us-LM8Il11zJ8-LPrPftBL2DMviSV7cLfF3avt7Dxfz7j3IFPYyNK7c2NrYfUxn6clxDmdy6-R2GdYS-sWW664YxdGnfG5ybYjyKjhHs2EE_VhFSk8Ysctr8snjmbZvg1f15USw-f1rc3Fbzb19mN9fzyjEpxkpgRxnTNRGagwKPMmKodrXzVnquVU2gXi65r8FTBcsdxtoLjgVgrulFMTvI1sFuzBCbzsY7E2xj9oUQV8bGPGkLRiJfI0Q40lIxrLWSXNWU8KXznHnJs9aHg9YwLTuoXZ4u2vZE9PSmb9ZmFbaGUca1JFkAHc1sYciLSY8cHasudIYgLlRuubx_M4ZfE6TRdE1y0La2hzAlg4VQhHEs5f9QiaACK5qpbx9RN2GKff4HQwjLOaJU7-y-O7BcDClF8A9uMTK7EJocQnMIYSa_-Xc5D9Rj6uhfA9XZkQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2240213392</pqid></control><display><type>article</type><title>Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia</title><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Terzić, Tea ; Kastelic, Matej ; Dolžan, Vita ; Plesničar, Blanka Kores</creator><creatorcontrib>Terzić, Tea ; Kastelic, Matej ; Dolžan, Vita ; Plesničar, Blanka Kores</creatorcontrib><description>This study aimed to explore the influence of two genetic polymorphisms of the 5-hydroxytryptamine 1A receptor (5-HT1A) and solute carrier family 6, member 4 (SLC6A4) genes on the clinical symptoms and treatment resistance in Slovenian patients with schizophrenia. A total of 138 patients with schizophrenia were evaluated using the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Clinical Global Impression, and Global Assessment of Functioning. Based on the selected criteria, 94 patients were included in the treatment-responsive and 44 in the treatment-resistant group. All subjects and 94 controls were genotyped for the 5-HT1A rs6295 and 5-HTTLPR polymorphisms. There were no statistically significant differences in the frequencies of these polymorphisms between the patients with schizophrenia and the control group and between the treatment-resistant and treatment-responsive group of schizophrenia patients. Polymorphisms rs6295 and 5-HTTLPR had an influence on the Global Assessment of Functioning scale score, while 5-HTTLPR also had an influence on the total score of the negative subscale within the Positive and Negative Syndrome Scale. Although we found no effect on progression toward the treatment-resistant schizophrenia, our data suggest that the rs6295 and 5-HTTLPR polymorphisms can influence some clinical symptoms in schizophrenia.</description><identifier>ISSN: 1176-6328</identifier><identifier>ISSN: 1178-2021</identifier><identifier>EISSN: 1178-2021</identifier><identifier>DOI: 10.2147/NDT.S76494</identifier><identifier>PMID: 25759587</identifier><language>eng</language><publisher>New Zealand: Taylor &amp; Francis Ltd</publisher><subject>Antipsychotics ; Blood &amp; organ donations ; Cognition &amp; reasoning ; Dopamine ; Equilibrium ; Genes ; genetic polymorphisms ; Mental disorders ; Neurosciences ; Original Research ; Patients ; Polymorphism ; Psychiatry ; Psychotropic drugs ; Schizophrenia ; serotonergic receptor ; serotonergic system ; Serotonin ; SLC6A4 ; Studies ; Suicides &amp; suicide attempts ; Treatment resistance</subject><ispartof>Neuropsychiatric disease and treatment, 2015-01, Vol.11 (default), p.453-459</ispartof><rights>2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2015 Terzić et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-61c3449d2695e8ef0d2640dcdcfa7f598d2edbb5fdef38ebdbb519f6516e1593</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2240213392/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2240213392?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25759587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terzić, Tea</creatorcontrib><creatorcontrib>Kastelic, Matej</creatorcontrib><creatorcontrib>Dolžan, Vita</creatorcontrib><creatorcontrib>Plesničar, Blanka Kores</creatorcontrib><title>Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia</title><title>Neuropsychiatric disease and treatment</title><addtitle>Neuropsychiatr Dis Treat</addtitle><description>This study aimed to explore the influence of two genetic polymorphisms of the 5-hydroxytryptamine 1A receptor (5-HT1A) and solute carrier family 6, member 4 (SLC6A4) genes on the clinical symptoms and treatment resistance in Slovenian patients with schizophrenia. A total of 138 patients with schizophrenia were evaluated using the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Clinical Global Impression, and Global Assessment of Functioning. Based on the selected criteria, 94 patients were included in the treatment-responsive and 44 in the treatment-resistant group. All subjects and 94 controls were genotyped for the 5-HT1A rs6295 and 5-HTTLPR polymorphisms. There were no statistically significant differences in the frequencies of these polymorphisms between the patients with schizophrenia and the control group and between the treatment-resistant and treatment-responsive group of schizophrenia patients. Polymorphisms rs6295 and 5-HTTLPR had an influence on the Global Assessment of Functioning scale score, while 5-HTTLPR also had an influence on the total score of the negative subscale within the Positive and Negative Syndrome Scale. Although we found no effect on progression toward the treatment-resistant schizophrenia, our data suggest that the rs6295 and 5-HTTLPR polymorphisms can influence some clinical symptoms in schizophrenia.</description><subject>Antipsychotics</subject><subject>Blood &amp; organ donations</subject><subject>Cognition &amp; reasoning</subject><subject>Dopamine</subject><subject>Equilibrium</subject><subject>Genes</subject><subject>genetic polymorphisms</subject><subject>Mental disorders</subject><subject>Neurosciences</subject><subject>Original Research</subject><subject>Patients</subject><subject>Polymorphism</subject><subject>Psychiatry</subject><subject>Psychotropic drugs</subject><subject>Schizophrenia</subject><subject>serotonergic receptor</subject><subject>serotonergic system</subject><subject>Serotonin</subject><subject>SLC6A4</subject><subject>Studies</subject><subject>Suicides &amp; suicide attempts</subject><subject>Treatment resistance</subject><issn>1176-6328</issn><issn>1178-2021</issn><issn>1178-2021</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNUstuEzEUHSEQLYUNH4BGYlMhTfH7sUGqyqORIkCQveV4rpOJZsaDPROpbPlxnKSpSFesfHR97vG516coXmN0RTCT779-XFz9lIJp9qQ4x1iqiiCCn-6xqAQl6qx4kdIGISq1Us-LM8Il11zJ8-LPrPftBL2DMviSV7cLfF3avt7Dxfz7j3IFPYyNK7c2NrYfUxn6clxDmdy6-R2GdYS-sWW664YxdGnfG5ybYjyKjhHs2EE_VhFSk8Ysctr8snjmbZvg1f15USw-f1rc3Fbzb19mN9fzyjEpxkpgRxnTNRGagwKPMmKodrXzVnquVU2gXi65r8FTBcsdxtoLjgVgrulFMTvI1sFuzBCbzsY7E2xj9oUQV8bGPGkLRiJfI0Q40lIxrLWSXNWU8KXznHnJs9aHg9YwLTuoXZ4u2vZE9PSmb9ZmFbaGUca1JFkAHc1sYciLSY8cHasudIYgLlRuubx_M4ZfE6TRdE1y0La2hzAlg4VQhHEs5f9QiaACK5qpbx9RN2GKff4HQwjLOaJU7-y-O7BcDClF8A9uMTK7EJocQnMIYSa_-Xc5D9Rj6uhfA9XZkQ</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Terzić, Tea</creator><creator>Kastelic, Matej</creator><creator>Dolžan, Vita</creator><creator>Plesničar, Blanka Kores</creator><general>Taylor &amp; Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150101</creationdate><title>Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia</title><author>Terzić, Tea ; Kastelic, Matej ; Dolžan, Vita ; Plesničar, Blanka Kores</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-61c3449d2695e8ef0d2640dcdcfa7f598d2edbb5fdef38ebdbb519f6516e1593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antipsychotics</topic><topic>Blood &amp; organ donations</topic><topic>Cognition &amp; reasoning</topic><topic>Dopamine</topic><topic>Equilibrium</topic><topic>Genes</topic><topic>genetic polymorphisms</topic><topic>Mental disorders</topic><topic>Neurosciences</topic><topic>Original Research</topic><topic>Patients</topic><topic>Polymorphism</topic><topic>Psychiatry</topic><topic>Psychotropic drugs</topic><topic>Schizophrenia</topic><topic>serotonergic receptor</topic><topic>serotonergic system</topic><topic>Serotonin</topic><topic>SLC6A4</topic><topic>Studies</topic><topic>Suicides &amp; suicide attempts</topic><topic>Treatment resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terzić, Tea</creatorcontrib><creatorcontrib>Kastelic, Matej</creatorcontrib><creatorcontrib>Dolžan, Vita</creatorcontrib><creatorcontrib>Plesničar, Blanka Kores</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Neuropsychiatric disease and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terzić, Tea</au><au>Kastelic, Matej</au><au>Dolžan, Vita</au><au>Plesničar, Blanka Kores</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia</atitle><jtitle>Neuropsychiatric disease and treatment</jtitle><addtitle>Neuropsychiatr Dis Treat</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>11</volume><issue>default</issue><spage>453</spage><epage>459</epage><pages>453-459</pages><issn>1176-6328</issn><issn>1178-2021</issn><eissn>1178-2021</eissn><abstract>This study aimed to explore the influence of two genetic polymorphisms of the 5-hydroxytryptamine 1A receptor (5-HT1A) and solute carrier family 6, member 4 (SLC6A4) genes on the clinical symptoms and treatment resistance in Slovenian patients with schizophrenia. A total of 138 patients with schizophrenia were evaluated using the Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Clinical Global Impression, and Global Assessment of Functioning. Based on the selected criteria, 94 patients were included in the treatment-responsive and 44 in the treatment-resistant group. All subjects and 94 controls were genotyped for the 5-HT1A rs6295 and 5-HTTLPR polymorphisms. There were no statistically significant differences in the frequencies of these polymorphisms between the patients with schizophrenia and the control group and between the treatment-resistant and treatment-responsive group of schizophrenia patients. Polymorphisms rs6295 and 5-HTTLPR had an influence on the Global Assessment of Functioning scale score, while 5-HTTLPR also had an influence on the total score of the negative subscale within the Positive and Negative Syndrome Scale. Although we found no effect on progression toward the treatment-resistant schizophrenia, our data suggest that the rs6295 and 5-HTTLPR polymorphisms can influence some clinical symptoms in schizophrenia.</abstract><cop>New Zealand</cop><pub>Taylor &amp; Francis Ltd</pub><pmid>25759587</pmid><doi>10.2147/NDT.S76494</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1176-6328
ispartof Neuropsychiatric disease and treatment, 2015-01, Vol.11 (default), p.453-459
issn 1176-6328
1178-2021
1178-2021
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_70fd0025097841998758d325bcf54f75
source Taylor & Francis Open Access; Publicly Available Content Database; PubMed Central
subjects Antipsychotics
Blood & organ donations
Cognition & reasoning
Dopamine
Equilibrium
Genes
genetic polymorphisms
Mental disorders
Neurosciences
Original Research
Patients
Polymorphism
Psychiatry
Psychotropic drugs
Schizophrenia
serotonergic receptor
serotonergic system
Serotonin
SLC6A4
Studies
Suicides & suicide attempts
Treatment resistance
title Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T15%3A05%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%205-HT1A%20and%205-HTTLPR%20genetic%20variants%20on%20the%20schizophrenia%20symptoms%20and%20occurrence%20of%20treatment-resistant%20schizophrenia&rft.jtitle=Neuropsychiatric%20disease%20and%20treatment&rft.au=Terzi%C4%87,%20Tea&rft.date=2015-01-01&rft.volume=11&rft.issue=default&rft.spage=453&rft.epage=459&rft.pages=453-459&rft.issn=1176-6328&rft.eissn=1178-2021&rft_id=info:doi/10.2147/NDT.S76494&rft_dat=%3Cproquest_doaj_%3E1668245177%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c476t-61c3449d2695e8ef0d2640dcdcfa7f598d2edbb5fdef38ebdbb519f6516e1593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2240213392&rft_id=info:pmid/25759587&rfr_iscdi=true